Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
130,367,883
-
Total 13F shares
-
56,024,124
-
Share change
-
-3,842,563
-
Total reported value
-
$243,509,430
-
Put/Call ratio
-
29%
-
Price per share
-
$4.34
-
Number of holders
-
79
-
Value change
-
-$20,551,922
-
Number of buys
-
37
-
Number of sells
-
31
Institutional Holders of Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) as of Q1 2022
As of 31 Mar 2022,
Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,024,124 shares.
The largest 10 holders included
AH Equity Partners Bio II, L.L.C., PERCEPTIVE ADVISORS LLC, Madrona Venture Group, LLC, VANGUARD GROUP INC, Comprehensive Financial Management LLC, Bain Capital Life Sciences Investors, LLC, Tikvah Management LLC, Amazon com Inc, ArchPoint Investors, and AH Equity Partners LSV II, L.L.C..
This page lists
79
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.